Amgen
Last updated Jun 15, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
5
Clinical Programs
0
Confidence Coverage
83%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Bispecific Antibodies
Highest priority development: FDA AP — ONTRUZANT (SUPPL)
Regulatory precedent
Why this matters: sets a safety guidance precedent in the same sub-indication (her2) as tarlatamab.
Competitive pressure: Low
Portfolio impact: Low
Evidence coverage: 83%
Active Signals
1
Investigate Priority
0
Opportunity Score
19
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 15, 2026Score 19Novel CD2-targeted bispecific antibody enhances T cell engagers for solid tumors
Oncology · Bispecific Antibodies
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — ONTRUZANT (SUPPL)Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — HERCEPTIN (SUPPL)Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — PHESGO (SUPPL)Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — ENHERTU (SUPPL)Moderate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Amgen right now?
- Which regulatory precedents should Amgen monitor in Oncology and Bispecific Antibodies?
- How does Emerging CD2 compare to the nearest competitive programs?
- What signals require immediate investigation for Amgen?
- Summarize the strategic implications of recent developments for Amgen.
- Where is the greatest uncertainty in Amgen's competitive positioning?